97 results
Page 2 of 5
6-K
EX-99.1
duntxy3kku5
17 Nov 22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
8:32am
6-K
EX-99.1
m3w3u8t 8bu7v6
26 Oct 22
RedHill Presents New Talicia® and Movantik® Data Analyses
7:02am
424B5
nmfd6a
11 May 22
Prospectus supplement for primary offering
8:47am
6-K
EX-99.1
o2s2n aksh0czb8
17 Mar 22
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
8:04am
6-K
EX-99.1
ol77rgm4meaoqkpqhazd
1 Mar 22
RedHill Announces Positive Phase 2 Study Results with Oral
9:03am
6-K
EX-1.1
ynqel52o9ceuqac
22 Nov 21
Current report (foreign)
4:54pm
424B5
wnlk log8j1y6bs
22 Nov 21
Prospectus supplement for primary offering
4:30pm
424B5
38dcqk7fay70b u7i8
18 Nov 21
Prospectus supplement for primary offering
4:17pm
424B3
pshrd8
9 Aug 21
Prospectus supplement
5:26pm
F-3
n84xu1z9
29 Jul 21
Shelf registration (foreign)
4:31pm
F-3
EX-1.2
bkmani9gjwwizrr
29 Jul 21
Shelf registration (foreign)
4:31pm
6-K
EX-1
tt19kjlac
21 May 21
RedHill Biopharma Presents a New Travelers’ Diarrhea
12:28pm
424B3
uyz3x8 rnlbo1
8 Apr 21
Prospectus supplement
4:38pm
F-3
n8hxh6u5zycd ywv7
30 Mar 21
Shelf registration (foreign)
8:00am
6-K
EX-1.1
xjn4z hj8vr4
4 Mar 21
Amended and Restated Underwriting Agreement
9:19am
424B5
pqw17 qcd9ipss
3 Mar 21
Prospectus supplement for primary offering
4:31pm
FWP
w1365gntv
1 Mar 21
Free writing prospectus
5:02pm
424B5
kbj 5nwrek0
1 Mar 21
Prospectus supplement for primary offering
4:56pm